This role supports the launch and ongoing promotion of therapies for metastatic triple-negative breast cancer within Gilead's Oncology team.
Base: $195,670.00 - $253,220.00; Bonus/Equity: Discretionary annual bonus and stock-based long-term incentives eligible; Benefits: Medical, dental, vision, life insurance, paid time off
Must-have
Nice-to-have
Not specified